Week In Review: Livzon In-Licenses GERD Therapy In $127 Million Agreement
March 18, 2023 at 15:40 PM EDT
Livzon Pharmaceutical Group entered a $127.5 million agreement for China rights to a gastroesophageal reflux disease therapy from Onconic Therapeutics. Meanwhile, Gracell Biotech announced that it had entered an unusual global deal with Seagen.
